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ABSTRACT 
Deoxyribonucleic acid, DNA is the source of various genetic information and is currently one of the most important and studied biological receptor. 
Lately, a wide range of chemotherapeutic agents are known wherein they affect cell division or DNA synthesis, leading to inhibition of cell growth 
and cell death. Out of various agents anthraquinone, having a planar tricyclic structure is the backbone of many known antitumor drugs like 
doxorubicin and mitoxantrone capable of targeting at the molecular/DNA level. This review embraces discussion on DNA-binding molecules with 
special attention to anthraquinone based compounds having application in anticancer activity by DNA damage mechanism. The review also 
compiles the work reported on anthraquinone based molecule in molecular imaging. 
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INTRODUCTION 
DNA is a nucleic acid (biomolecule) that contains the genetic 
instructions specifying the biological development of all cellular 
forms of life and is frequently stated as the molecule of heredity, as it 
is responsible for the genetic propagation of all traits [1-3]. During 
reproduction process, duplex DNA is replicated and transmitted to 
the offspring and its sequence describes various features from 
organism type through physical traits to disease susceptibility. DNA 
sequence is copied (transcription) onto RNA Biomolecules, which 
are then used in protein synthesis to encode a specific protein 
sequence (translation). (Bio)chemical sensor technologies that focus 
on the direct detection of nucleic acids (DNA and RNA) are currently 
an area of tremendous interest, as they play a major role in 
forensics, pharmaceutical applications, medical diagnosis, genetic 
screening etc. [4-7]. Small molecules which are capable of 
recognizing specific DNA sequences are potent tools for the 
interpretation of human genome and may serve as valuable 
therapeutic agents [8]. The structural features of double helix DNA 
comprises of two anti-parallel, complementary, sugar-phosphate 
poly-deoxyribonucleotide strands which are connected through 
hydrogen bonds between nucleotide bases [9]. The backbone of 
paired strands in DNA describes the helical grooves and within these 
grooves edges of heterocyclic bases are exposed outside. The 
structural depiction of DNA is shown in fig. 1 [10].  
 
 
Fig. 1: Structural depiction of DNA (source-wiki books, 2008) 
The chemical feature of the molecular surfaces in a given DNA 
sequence is distinct in either groove (major or minor) and forms the 
basis for duplex DNA molecular recognition by small molecules and 
proteins. In this article we have discussed about different modes of 
DNA binding with special attention to anthraquinone based 
compounds having application in anticancer activity by DNA damage 
mechanism. The review compiles the work reported from 1990 to 
till date on anthraquinone based molecule having application in 
anticancer activity and molecular imaging. 
Interactions of duplex DNA with small organic molecules 
The type of chemical interactions between small molecules and DNA 
is an important tool for the prediction of potential physiological 
and/or therapeutic consequences of such interactions. Broadly DNA 
interactions with small molecules can be classified as covalent and 
non covalent where non covalent interactions can be further 
classified as intercalation and groove binding.  
Covalent interaction of DNA with small organic molecules 
DNA alkylating agents are clinically important and are frequently 
used for the cancer chemotherapy and over the last two decades 
wide range of alkylating agents has been synthesized. Fig. 2 shows 
few of the leading examples of DNA alkylating agents. Alkylating 
agents preferentially reacts with N-7 position of guanine and N-3 of 
adenine nucleobases present in DNA which inhibits the base pairing 
of the DNA leading to miscoding of DNA. This alteration in DNA leads 
to its fragmentation by repair enzymes which replace the alkylated 
bases of double helix. Another mechanism of DNA damage by 
alkylating agents is the formation of cross-bridges i.e., bonds 
formation between atoms present in the DNA that prevents DNA 
from being separated for synthesis or transcription. The third 
mechanism of action of alkylating agents causes mispairing of the 
nucleotides leading to mutations.  
The nitrogen mustard was the first DNA alkylating agent used 
medically, as well as the first modern cancer chemotherapies [11]. 
Another classic example which is most widely used as a DNA 
alkylating agent is cyclosporamide. Cisplatin (cis-diammine-dichloro 
platinum) is a well-known covalent DNA binder used as an 
anticancer drug which makes an intra/inter strand cross-link with 
the nitrogen’s present on the DNA bases and is extensively used in 
treatment of testicular, ovarian, head, and neck cancers [12]. The 
success of cisplatin as an anticancer drug has led to the development 
of other less toxic derivatives such as carboplatin [13]. 
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Fig. 2: Examples of DNA alkylating agents 
 
Non-covalent interactions of small molecules with duplex DNA 
DNA intercalators 
Planar aromatic molecules bind with DNA by a process named as 
intercalation which is established for a variety of polycyclic aromatic 
systems termed as intercalators. The DNA intercalation is 
characterized by insertion of planar aromatic rings between the 
DNA base pairs and is generally independent of base pair sequence. 
Intercalation requires changes in the sugar-phosphate torsional 
angles to accommodate the aromatic compound which is 
accompanied by other changes in the helical parameters such as 
unwinding, bending, etc. [14-16]. This interaction is quite strong 
despite the fact that energy is utilized to unwind the helix and un-
stack the base pairs to allow the complex formation. The stability of 
intercalation complexes is governed by van der Waals, electrostatic 
and hydrophobic forces. Molecules that bind to double-stranded 
DNA (ds-DNA) by interactive mode have been significantly used as 
drugs as shown in fig. 3 [17]. The two major types of intercalation 




Fig. 3: Chemical structures of some DNA intercalators 
 
DNA stain, Ethidium bromide (EtBr) and antimalarial quinacrine 
demonstrate intercalating DNA binding by stacking interaction of 
the respective heteroaromatic rings present in their structure with 
the DNA base pairs [18]. The cationic side chain present in 
quinacrine contributes to complex stability by electrostatic 
interactions with the negative phosphate units of the groove. A 
number of other classical intercalators are used including the 
anthracyclines and actinomycin [19]. Intercalation preferentially 
occurs at G/C-rich sequences, because these sequences get un-
stacked easily. Intercalators generally cause more significant 
distortion of the native conformations of DNA.  
Threading intercalators usually have two side chains on the opposite 
sides of a planar aromatic ring system, and the process of complex 
formation with DNA is more complicated where one of the side 
chains of the system slides through the intercalation cavity to form 
the stable complex. The complex stability of the threading intercalators 
is due to the favorable interactions of the side chains with both the major 
and minor grooves. Nogalomycin and Daunomycin are the leading 
example of the threading intercalators [20]. 
DNA groove binders 
Groove binders are a major class of small molecules that bind to ds-
DNA and play an important role in drug development. Small 
molecules can bind to both the major or minor groove of ds-DNA. 
Due to the dimensional difference in grooves vastly dissimilar and 
different shaped molecules are required to target them. Major 
grooves are the site for binding of many DNA interacting proteins 
and only limited molecules that bind to the DNA major groove are 
reported [21, 22]. 
Major groove binding small organic molecules  
Proteins usually bind to DNA by major groove after recognition and 
reading the sequence information. However, non-peptidyl 
compounds bind with the minor groove, thus possibly allowing 
simultaneous major groove recognition by proteins [23]. Therefore, 
it is desirable to have a major groove binding molecule that could 
block access to proteins that recognize the same groove. Duplexes 
made up of polypurine–polypyrimidine sequences can be read by 
oligomer that bind in the major groove and form hydrogen bond 
with bases of the purine strand and termed as triplex-forming 
oligonucleotides (TFOs) [24].  
An alternate form of major groove recognition is achieved by 
peptide nucleic acids (PNAs) which are different from TFOs. The 
backbone of TFOs are oligonucleotides or their modified analogues, 
whereas PNAs have a peptide-like backbone secondly TFOs can bind 
within the existing major groove of DNA, whereas PNAs attack the 
helix to form a triplex, which then results in the displacement of 
noncomplementary oligopyrimidine DNA strand, fig. 4 [25, 26]. In 
order to target the major groove, it is essential to modulate 
biological processes like, transcription artificially. 
 
 
Fig. 4: Chemical structure of peptide nucleic acid (PNA) 
 
Minor groove binding small molecules 
Minor groove binders (MGBs) represent an interesting class which 
has shown highly effective in vitro and in vivo preclinical tumor 
models unresponsive to other antineoplastic agents [27-29]. Minor 
groove binding involves greater binding affinity and higher 
sequence specificity than that of intercalators binding. DNA minor 
groove binding is demonstrated for neutral, mono-charged and 
multi-charged ligands. The dominant forces for small molecule–
minor-groove binding interactions are van der Waals, electrostatic, 
hydrogen and hydrophobic bonding. Sequence specificity is 
attributed to hydrogen-bonds between the small molecule and base 
pairs. The design of low molecular mass compounds that can bind 
with high affinity and specificity to pre-determined DNA sequences 
(10–16 base pairs long) is of great importance in chemical biology 
[30]. Minor groove binders frequently show pronounced AT 
selectivity. 
 Several factors contribute to preference like-i) AT-rich grooves have 
higher electrostatic potential than in the GC-filled ones which lead to 
AT selectivity for the dicationic small molecules, ii) dimensions of 
the minor groove at AT sites are narrower and deeper than GC 
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locations. The topology at AT sites allows for easier filling and greater 
van der Waals contacts by small molecules, the amino group of G in GC 
locations protrudes into the groove, thus prohibiting van der Waals 
contacts comparatively to those achievable at the AT sites. The cationic 
minor groove binders include the natural products Netropsin and 
Distamycin and the synthetic molecules DAPI and Berenil [31-33]. 
DNA binding polyamides composed of N-methyl imidazole (Im), N-
methyl pyrrole (Py), and N-methyl-3-hydroxypyrrole (Hp) are 
crescent-shaped molecules that bind to the minor groove as 
antiparallel dimers. Bhattacharya and co-workers have reported some 
longer distamycin analogues without the leading amides resulted in 
high affinity and specificity towards AT-specific stretches of ds-DNA. 
The synthetic bis-(benzimidazole) derivative Hoechst 33258 is widely 
used for chromosome staining and also possesses antitumor activity 
apart from serving as an inhibitor of DNA topoisomerase I [34-36]. 
Chemical structures of few minor grove binders are shown in fig. 5. 
 
 
Fig. 5: Chemical structures of DNA minor groove binders 
 
 
Fig. 6: Structure of net amsa 
 
Intercalator-minor groove binding hybrid molecules 
Hybrid molecules commonly bind to DNA by intercalation between 
the DNA base pairs or through binding in the DNA minor groove. 
Hybrid molecules contain both intercalating and minor groove 
binding functionalities and interact more strongly with DNA than 
those having either of the individual functionality thereby have a 
prolonged residence time on DNA allowing them to interfere with 
DNA processing enzymes [37, 38]. These hybrid molecules are also 
known as combilexins due to their dual binding mode of action and 
are usually composed of intercalators based on analogues of 
ellipticine, amsacrine, anthraquinones and minor groove binders 
based on analogues of netropsin or distamycin A, etc. The design of 
DNA threading complexions provides an original way for the 
development of sequence-specific ligands capable of forming stable 
complexes with DNA. Combilexins have enhanced DNA sequence 
specificity compared to mono-intercalators or minor groove binders. 
The well-known and potent antitumor drug, Net Amsa (structure shown 
in fig. 6) is a good example of the combilexins which is derived from a 
covalent combination of the minor groove binder, netropsin and the 
intercalators, amsacrine. The molecule shows three modes of binding 
with duplex DNA: (i) sequence-specific recognition of the minor groove 
of the DNA double helix via the netropsin moiety; (ii) intercalation of the 
acridine chromophore inside the duplex DNA, and (iii) threading of the 
methane sulfonanilino group into the major groove.  
DNA intercalators as anticancer drugs  
Intercalators are one of the most important groups of 
compounds that interact reversibly with the DNA double helix. 
Some of them are valuable drugs currently used for the 
treatment of different cancers like ovarian cancer, breast 
cancers, and acute leukemias while many others are in different 
phases of clinical trials. All the intercalating agents share 
common structural features such as the presence of planar 
polyaromatic systems which bind by insertion between DNA 
base pairs, with a preference for 5'-pyrimidine-purine-3' steps. 
The chromophores are linked to basic chains that might also play 
an important role in the affinity and selectivity shown by these 
compounds. It is well established that the antitumor property of 
intercalators is related to their ability to stabilize the DNA-
intercalator-topoisomerase II ternary complex. 
Few of the known intercalators are summarized in fig. 7. There are 
many intercalators reported in literature including (1) 
naphthalimide and related compounds like Mitonafide and 
Amonafide that are extensively tested in clinical trials. (2) 
pyridocarbazole system like Ellipticine and 9-Methoxyellipticine 
display antineoplastic property, (3) acridine and related compounds 
like Amsacrine, a drug currently used in the treatment of acute 
leukemias and malignant lymphomas [39-41].  
But anthraquinone based intercalators are the most famous ones 
with the presence of anthraquinone ring system several antitumor 
drugs such as, Daunomycin (Daunorubicin), Ametantrone, 
Mitoxantrone and Doxorubicin (Adriamycin). The antitumor 
anthracyclines exert their cytotoxic activity involves (i) interaction 
with DNA, preferentially at 5'-pyrimidinepurine-3' GC-rich sites 
wherein the planarity of the anthraquinone ring allows an 
intercalation between base pairs of DNA in the B conformation. 
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Fig. 7: Structure of well-known DNA intercalators 
 
Anthraquinone as DNA targeting probe 
After the structure revelation of DNA by Watson and Crick in 1953 
several established therapeutic modalities have been established for 
targeting DNA like antimetabolites, which deplete nucleotides, eg., 
methotrexate; alkylating agents, which cause DNA damage, eg., 
nitrogen mustard and its derivatives; and intercalators which bind 
to DNA and inhibit the activity of many enzymes which utilizes DNA 
as a substrate eg., actinomycin. Among the most widely and 
successfully used anticancer agents are the non-specific DNA 
damaging chemicals which include topo isomerases inhibitors 
(TOPO) I and II, alkylating agents, antimetabolites, and agents 
responsible for covalent modification of DNA (mitomycin C and 
platinum compounds) [42-44]. Despite phenomenal advances in the 
understanding of the diseases, cancer still remains the leading cause 
of death worldwide. Therefore, new strategies for combined 
diagnostic and therapeutic is imperative for early diagnosis of 
cancer and appropriate therapeutic strategy [45].  
In addition to the surgical removal of tumor tissue, another mode of 
pretreatment includes chemotherapy, radiotherapy and immuno-
therapy. There is continuing interest in the development of new 
agents in which the small molecule tricyclic anthraquinone 
structural motif represents an attractive target for the rational 
design of new anticancer agents due to its central role in the control 
of cellular proliferation [46, 47]. A wide range of chemotherapeutic 
agents are known wherein they affect cell division or DNA synthesis 
leading to inhibition of cell growth and cell death.  
 
 
Fig. 8: Structure of anthraquinone-based anticancer drugs 
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There is a continuing interest for the development of new agents in 
which anthraquinone base structure represents an attractive target 
for the design of new anticancer agent due to its strong role in the 
control of cell proliferation [48-50]. Anthracyclines/anthraquinones 
from both natural and semisynthetic sources are among the most 
widely used chemotherapeutic agents and are effective for a broad 
spectrum of solid tumors and leukemias [51, 52]. Anthraquinone-
based compounds occupies a prominent position in cancer 
chemotherapy, with the naturally occurring aminoglycoside 
anthracycline doxorubicin and the amino-anthraquinone 
mitoxantrone both having planar tricyclic structure is the backbone 
being in clinical use [53]. These and other experimental anthraquinone 
derivatives are believed to act at the duplex DNA level, probably 
through the stabilization of a ternary complex with DNA. 
They are known for their foremost property of intercalation 
between the DNA base pairs causing an unwinding of the helix 
leading to miscoding and possible cell apoptosis. Although the 
mechanism of action of the antitumor activity of the anthracene-
9,10-diones is probably multimodal in nature, a wide range of 
studies has indicated that an interactive interaction with DNA may 
be a major cellular event where the planar tricyclic system 
intercalate into DNA base pairs and interfere in the transcription 
and replication processes of the cell. 
DNA serve as a target of anticancer drug discovery and a variety of 
compounds have been developed with anticancer activity displayed to 
target DNA either directly or through inhibition of enzymes that control 
DNA integrity or provide building blocks for DNA. The rationale for DNA 
targeting for cancer treatment is based on three facts:  
a. ‘Broken DNA’ in tumor cells (gene mutations);  
b. Life cycle of DNA is different in tumor cells from normal cells; and  
c. Tumor cells (as compared with normal cells) acquire additional 
DNA damage, due to higher DNA replication, deficits in 
checkpoint control and DNA repair process.  
Alteration of cellular DNA can be considered for targeted therapy 
since rapidly proliferating tumor cells depend on upon DNA 
integrity more than normal quiescent cells. DNA-based cancer 
therapy is well acceptable but least successful due to- 
a. Not effectiveness to cure cancer;  
b. Significant adverse side effects; and 
c. Cause secondary cancers (cancers not related to primary cancer 
and appearing 10–15 y after successful elimination of the 
primary disease).  
Therefore, there is an interest in the modification strategy of DNA 
targeting as an anticancer therapy to achieve two improvements: i) 
increased specificity towards tumor cells as compared to normal 
cells by taking advantage of the greater dependence of tumor cells 
on certain DNA-related processes, and ii) elimination of adverse side 
effects including secondary cancer, by using compounds that bind to 
DNA, but do not damage it. Famously used anthraquinone based 
anticancer drugs structures are shown in fig. 8.  
Many anthraquinone based derivatives are reported but particularly the 
promising clinical activity was observed with 1, 4-bis ((aminoalkyl) 
amino) anthracene-9,10-diones-substituted anthraquinone; mito-
xantrone and ametantrone which led to numerous pharmacological 
studies [54-62]. Tricyclic core comprising agents like 1,3-dihydroxy-
9,10-anthraquinone (DHA), 1-hydroxy-3-(3-alkyl aminopropoxy)-9,10-
anthraquinone (MHA) and 3-(3-alkyl aminopropoxy)-9,10-
anthraquinone (NHA), pyrrole [2,1-c][1,4] benzodiazepine-anthra-
quinone conjugates are potent antitumor agents, which lead to tumor 
cell apoptosis (structure shown in fig. 9) [63-68].  
Substituted anthraquinone derivatives also represent as potential 
anticancer drugs that target G-quadruplex structures of DNA 
through its stabilization [69-72]. Anthraquinone derivatives like 
cationic porphyrin–anthraquinone dyads target the G-quadruplex 
DNA by π-π interactions whereas the cationic side chains interact 
with the negatively charged phosphate backbones present in G-
quadruplex, as shown in fig. 10 [73]. 
 




Fig. 10: Structure of cationic porphyrin-anthraquinone dyads [73] 
 
They are also known to stabilize G-quadruplex by acting at the 
telomeric region of DNA [74]. The 3′-ends of eukaryotic 
chromosomes consist of poly nucleotides comprising several kilo 
bases with tandem repeats of the same base sequence (e. g., 5′-
TTAGGG in humans) termed as a telomere, ribonucleoprotein in 
nature and serves to protect the chromosomal termini from end-to-
end recombination and attack by exonuclease enzymes. The 
telomere region of DNA is not conserved during cell division thus led 
to the hypothesis that the length of the telomere correlates with the 
capacity of cells to replicate. Most human cells can only divide 50–60 
times before senescence occurs and the cells enter a cycle of 
programmed cell death (apoptosis). Thus, the telomere length is a 
‘biological clock’ capable of determining the proliferative capacity of 
most human somatic cells. Certain cell types (e. g., germ cells, stem 
cells and essentially immortal cells such as those found in 
neoplasms) have been shown to regulate their telomeres to nearly 
constant length by expressing a specialized RNA-dependent DNA 
polymerase called telomerase expressed in>85% of cancers, 
including breast and gastric cancer while the enzyme was not 
detectable in healthy somatic cells. 
 
 
Fig. 11: Structure of Pt-1C3 [76] 
 
Consequently, telomerase became an obligate focus for anti-cancer 
research as it promised a unique target for chemotherapy without 
the associated side effects of conventional chemotherapeutics. DNA 
sequences that are rich in guanines can adopt unusual secondary 
DNA structural forms. In particular, four guanine bases can associate 
in a planar, hydrogen bonded assembly called a G-tetrad (or quartet) 
where each guanine simultaneously accepts and donates two 
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hydrogen bonds in a reverse-Hoogsteen arrangement. Successive 
layers of G-tetrads allow such single stranded DNA to adopt a high-
order fold-back structure in solution termed a G-tetraplex (or 
‘quadruplex’). Telomerase requires access to a single-stranded 
region of telomeric DNA in order to bring about the required 
elongation and telomere extension by telomerase could be inhibited 
if agents could be found that acted to stabilize the folded G-tetraplex 
structure. Derivatives of anthraquinone are also stated as effective 
inhibitors of c-Met Kinase (product of the MET proto-oncogene) 
pathway and could be useful for cancer therapy [75].  
Interestingly anthraquinone tethered platinum complexes (Pt-1C3) 
have been shown to accumulate in cancer cell spheroids (useful 
models for tumors), demonstrating improved cellular accumulation 
over cisplatin, fig. 11 [76]. Novel esters of chlorambucil with 1,4-
dihydroxy-9,10-anthraquinone derivative tested for antitumor 
activity in mice bearing S-180 ascitic cells as cytotoxic activity 
against L1210 cells [77]. Cationic anthraquinone derivatives a 
synthesized through click chemistry are reported, which induces 
apoptosis in BGC gastric cancer cells which might involve bursting of 
DNA-damaging ROS disrupting redox homeostasis in cells and 
activate mitochondrial permeability transition, resulting in a loss of 
mitochondrial membrane potential (ѱm) [78,79]. Amino-acyl-
hydroxy-anthraquinone bearing glycyl, valyl, lysyl and tryptophanyl 
residues, 1,4-bis(2-amino-ethylamino) anthraquinone-amino acid 
conjugates and 1,4-diamido anthraquinone derivatives were 
reported to exhibit significant DNA binding (intercalation), 
cytostatic or cytotoxic activities in cancer cells [80-82]. Hydroxy-
anthraquinone based derivatives have been identified as the 
biologically active site within anthracycline-based antitumor 
therapeutics and are also naturally occurring and extractable from 
selected plant life.  
Biological effects of anthraquinone  
Anthraquinones/Anthracycline that has obtained clinical approval 
includes pirarubicin, aclarubicin, and mitoxantrone. Pirarubicin, a 4-
tetrahydropyranyl doxorubicin induces much less cardiotoxicity 
than doxorubicin in animal models, but clinical studies indicated 
severe cardiac dysfunction in humans [83-84]. Aclarubicin, a 
trisaccharide anthracycline is active (with tolerable side effects) in 
acute myeloblastic leukemia patients [85].  
Mitoxantrone is active in breast cancer, non-Hodgkin's lymphoma, 
acute promyelocytic and myelogenous leukemias, as well as 
androgen-independent prostate cancer. Due to diverse molecular 
effects of anthraquinones, their cytotoxic mechanism involves 
multiple pathways. The mechanism of anti-angiogenic effects of the 
anthraquinones responsive of their antitumor properties includes- 
1) Intercalation into DNA, leading to inhibited synthesis of 
macromolecules (DNA, RNA and proteins);  
2) Generation of free radicals, leading to DNA damage and/or lipid 
peroxidation;  
3) DNA binding and alkylation;  
4) DNA cross-linking;  
5) Interference with DNA unwinding or DNA strand separation;  
6) Inhibition of helicase activity;  
7) Direct membrane effects; and  
8) Inhibition of topoisomerase I. 
  
 
Fig. 12: Biological effect of doxorubicin, an anthraquinone based anticancer drug 
 
There is compelling evidence that cellular DNA is the primary target 
of anthracyclines. The anthraquinone ring intercalates between DNA 
base pairs, with its long axis nearly perpendicular to the axis of the 
double helix. One of the rings acts as an anchor and stabilizes the 
complex through hydrogen bond interactions as the daunosamine 
sugar lies in the minor groove. The occurrence of a single positive 
charge on daunomycin contributes electrostatically to the binding 
[86]. The concentrations of anthracyclines used in clinical practice 
caused the formation of protein-associated DNA single and double-
strand breaks that were affected by topoisomerase II inhibition. 
DNA lesions caused by the formation of free radicals and reactivity 
on the DNA backbone occurred when cells were treated with 
doxorubicin at concentrations that were too high for patient use 
[87]. However, at clinically relevant concentrations, anthracyclines 
do not induce lipid peroxidation in cancer cells [88]. Doxorubicin 
derivatives can generate reactive oxygen species (ROS). These 
species can damage cell membranes and bio-molecules, which can, 
in turn, induce apoptosis, as shown in fig. 12. 
Anthraquinone in imaging 
Macrocyclic complexes linked with DNA binding agents are started 
to display sequence selective interaction with DNA depending on the 
metal ion, nature of the agent and nature of the linker used eg., N-
substituted cyclam-amino acid conjugates interacts with DNA in a 
highly selective manner, fig. 13 [89,90]. The localization of 
macrocyclic metal complexes on DNA is of interest for a number of 
reasons. If the metal ion is a radionuclide, increased DNA damage 
will result, if it is a metal that facilitates phosphate hydrolysis, then 
DNA cleavage may result and if the metal binds to DNA bases, then 
sequence-selective binding can occur [91-96].  
 
 
Fig. 13: Cyclam/Anthraquinone macrocycle/intercalators 
complex [89] 
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Intercalators bind rapidly and reversibly to DNA and have been 
shown to increase the rate and extent of DNA binding of a variety of 
groups including metal complexes. A series of macrocyclic 
complexes linked to intercalators have been reported in the 
literature which interacts in a sequence-selective manner with DNA. 
The sequence selectivity depends on the metal ion, the nature of the 
intercalator and the nature and position of the link between the 
macrocycle and the intercalators. In all of these studies the 
macrocycle employed was the 12-membered ring, cyclen (1,4,7,10-
tetraazacyclododecane), a ligand that forces the metal to lie out of 
the coordination plane promoting interactions with the DNA. 
Gadolinium complexes of 1,4-and 1,5-diaminoanthraquinone 
conjugated DOTA based compound are reported to bind with 
specific DNA sequence open-d(ATCGAGACGTCTCGAT)2 [97-99]. 
Recently, mono and dimetallic Au (I) triphenylphosphine complexes 
derived from 1,2-, 1,4-, and 1,8-dialkynyloxyanthraquinone have 
been synthesized, and their cytotoxicity on cancer cell line (MCF-7) 
and cell fluorescence imaging have been reported. 1,4-and 1,8-Bis-
substituted anthracene dione derivatives inhibit the activity of 
telomerase [100]. In nuclear imaging, use of stable complexes with 
radio metal is a crucial factor for the development of metal-based 
imaging and a therapeutic agent. The lanthanide (trivalent) 
complexes of poly aza poly carboxylic macrocycle with seven to eight 
donor atoms such as with DOTA are known for their strong 
complexation stability, unusually rigid, highly symmetrical structure 
and adopting same geometry in solution as well as the solid state in 
comparison with non-cyclic ligands such as DTPA even though both 
are octa dentate chelate. Though anthraquinone moiety has been 
much explored for cellular/in vitro imaging but in vivo studies using, 
radioisotopes have not yet been exploited in detail. Recently, 
anthraquinone derivative conjugated with DO3A has been synthesized 
and labeled with [68] Ga (for PET), [99]mTc (for SPECT) and exhibited 
very promising results [101,102]. 
CONCLUSION 
In this article, we have made an attempt to review recent research in 
drug designing and development for cancer having anthraquinone 
core. All the DNA binding modes, the biological effect of these drugs 
on DNA and ongoing research on anthraquinone based compounds 
having anticancer application has been very well discussed to 
understand deeply the idea behind designing new DNA-targeted 
drugs. In conclusion, anthraquinone based molecules are important 
categories of drugs and can be potentially targeted towards research 
and development for the treatment and imaging of cancer. 
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